Vasseur, Damien http://orcid.org/0000-0001-8787-1498
Arbab, Ahmadreza http://orcid.org/0000-0002-7015-0448
Giudici, Fabiola
Marzac, Christophe
Michiels, Stefan http://orcid.org/0000-0002-6963-2968
Tagliamento, Marco http://orcid.org/0000-0001-7461-023X
Bayle, Arnaud
Smolenschi, Cristina
Sakkal, Madona
Aldea, Mihaela http://orcid.org/0000-0001-7685-051X
Sassi, Hela
Dall’Olio, Filippo Gustavo
Pata-Merci, Noémie
Cotteret, Sophie
Fiévet, Alice
Auger, Nathalie http://orcid.org/0000-0002-9744-4470
Friboulet, Luc http://orcid.org/0000-0002-1129-4978
Facchinetti, Francesco http://orcid.org/0000-0001-6313-6341
Géraud, Arthur
Ponce, Santiago
Hollebecque, Antoine http://orcid.org/0000-0003-2869-7551
Besse, Benjamin
Micol, Jean Baptiste
Italiano, Antoine
Lacroix, Ludovic http://orcid.org/0000-0003-2535-1010
Rouleau, Etienne
Article History
Received: 11 June 2023
Accepted: 15 February 2024
First Online: 26 February 2024
Competing interests
: D.V.: no disclosures. A.A.: no disclosures. F.G.: no disclosures. C.M.: None related to the current manuscript. S.M.: outside the scope of the submitted work, fees for statistical advice to IDDI, Amaris, Roche and for Data and safety monitoring membership of clinical trials: IQVIA, Sensorion, Biophytis, Servier, Yuhan. M.T.: Travel grants: Roche, Bristol-Myers Squibb, AstraZeneca, Takeda, Eli Lilly. Honoraria as medical writer: Novartis, Amgen, Merck Sharp & Dohme. None related to the current manuscript. A.B.: As part of the Drug Development Department (DITEP) = . Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Adlai Nortye USA Inc, Aduro Biotech, Agios Pharmaceuticals, Amgen, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, BicycleTx Ltd, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Casi Pharmaceuticals, Inc, Celgene Corporation, Cellcentric, Chugai Pharmaceutical Co, Cullinan-Apollo, Curevarc, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Tharapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Incyte Corporation, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Janssen R&D LLC, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Genomics, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre Medicament, Relay Therapeutics, Inc, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Transgene S.A, Turning Point Therapeutics, Xencor. Research Grants from Astrazeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from Astrazeneca, BMS, Boringher Ingelheim, GSK, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. C.S.: None related to the current manuscript. MS: None related to the current manuscript. M.A.: Expenses from Sandoz. H.S.: no disclosures. F.D.O.: no disclosures. N.P.M.: no disclosures. S.C.: no disclosures. A.F.: no disclosures. N.A.: no disclosures. L.F.: Research funding from Debiopharm, Incyte, Relay Therapeutics and Nuvalent and Non financial support from Illumina Inc and Guardant Health. F.F.: no disclosures. A.G.: None related to the current manuscript. S.P.: None related to the current manuscript. A.H.: Basilea, Debiopharm, EISAI, Incyte, QED Therapeutics, Relay Theraeutics, Servier, Tahio, AstraZeneca (Funding, Institutional, Financial interest), Incyte (Funding, Institutional, Financial interest). B.B.: No personal financial disclosures, Sponsored Research at Gustave Roussy Cancer Center. 4D Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Chugai pharmaceutical, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, EISAI, Genzyme Corporation, GSK, Inivata, IPSEN, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals, Turning Point Therapeutics. JM: Abbvie, Jazz Pharmaceuticals and Astellas. A.I.: Research Grant: AstraZeneca, Bayer, BMS, Merck, MSD, Pharmamar, Roche Advisory Board: AstraZeneca, Bayer, Deciphera, Daiichi Sanky, Novartis Roche. L.L.: Hospitalities, Travel, advice board, research grant last 5 years with: Abbott; Adept Field Solutions; Amgen ; AstraZeneca; Beckman Coulter; Bayer Boeringer; BMS; Icomed; Illumina, Genomic Health; Guardant health; Lilly; Medimmune; Myriad; Novartis; Pfizer; QualWorld1; Roche; Siemens Healthineer; Taiho Oncology, Thermofisher Sc; VelaDx. E.R.: Travel, advice board, research grant : AstraZeneca, Roche, BMS, GSK, and Clovis.